Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1264
Source ID: NCT00741585
Associated Drug: Any Antihypertensive Medication Alone Or In Combination
Title: Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
Acronym: HYGIA
Status: COMPLETED
Study Results: NO
Results:
Conditions: Essential Hypertension|Cardiovascular Disease|Stroke|Chronic Kidney Disease
Interventions: DRUG: Any antihypertensive medication alone or in combination|DRUG: Any antihypertensive medication alone or in combination|DEVICE: Ambulatory blood pressure monitoring
Outcome Measures: Primary: To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment., Yearly evaluation for at least ten years | Secondary: To evaluate the influence of circadian time of treatment in BP control of hypertensive patients., Yearly evaluation for at least ten years|To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment., Yearly evaluation for at least ten years|To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile., Yearly evaluation for at least ten years|To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile., Yearly evaluation for at least ten years|To evaluate, for all groups of interest, the prevalence and vascular, metabolic, and renal risk profile of white-coat hypertension., Yearly evaluation for at least ten years|To evaluate, for all groups of interest, the prevalence and vascular, metabolic, and renal risk profile of masked hypertension., Yearly evaluation for at least ten years|To evaluate, for all previous objectives, potential differences between men and women., Yearly evaluation for at least ten years|To evaluate the impact of changes in ambulatory BP in vascular, metabolic, and renal risk assessment., Yearly evaluation for at least ten years
Sponsor/Collaborators: Sponsor: University of Vigo | Collaborators: Servicio Gallego de Salud
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 21983
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2008-09-01
Completion Date: 2018-06-30
Results First Posted:
Last Update Posted: 2018-08-28
Locations: CS Friol, Friol, Lugo, 27220, Spain|CS Baiona, Baiona, Pontevedra, 36300, Spain|CS Bueu, Bueu, Pontevedra, 36930, Spain|CS A Estrada, La Estrada, Pontevedra, 26680, Spain|CS A Guarda, La Guardia, Pontevedra, 36780, Spain|CS Valmiñor, Nigran, Pontevedra, 36250, Spain|CS Panxón, Nigrán, Pontevedra, 36340, Spain|CS Tomiño, Tomiño, Pontevedra, 36200, Spain|Bioengineering & Chronobilogy Labs., University of Vigo, Vigo, Pontevedra, 36200, Spain|Hospital do Meixoeiro, Vigo, Pontevedra, 36200, Spain|CS Calle Cuba, Vigo, Pontevedra, 36202, Spain|CS A Doblada, Vigo, Pontevedra, 36205, Spain|CS Coia, Vigo, Pontevedra, 36209, Spain|CS Sardoma, Vigo, Pontevedra, 36214, Spain|CS Teis, Vigo, Pontevedra, 36216, Spain|CS Vilaboa, Vilaboa, Pontevedra, 36141, Spain|CS San Roque, Vilagarcía De Arousa, Pontevedra, 36600, Spain|CS Fingoi, Lugo, 27002, Spain|Complexo Hospitalario Universitario de Ourense, Orense, 32005, Spain|CS Lerez, Pontevedra, 36156, Spain
URL: https://clinicaltrials.gov/show/NCT00741585